Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CGEN NASDAQ:PYRGF NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$8.81+20.2%$7.91$4.66▼$9.90$144.66M0.6821,525 shs201,976 shsCGENCompugen$1.34-4.3%$1.49$1.13▼$2.66$119.58M2.58232,459 shs631,966 shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$36.19M0.8114,627 shs2,403 shsSKYESkye Bioscience$4.25-0.2%$3.72$1.14▼$6.22$131.71M2.34274,437 shs242,412 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+16.07%-5.47%+28.80%+880,999,900.00%CGENCompugen0.00%-6.29%-6.29%-18.79%-31.98%PYRGFPyroGenesis Canada0.00%+1.53%-25.22%-45.06%-67.86%SKYESkye Bioscience0.00%+6.25%+21.08%+99.06%-29.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$8.81+20.2%$7.91$4.66▼$9.90$144.66M0.6821,525 shs201,976 shsCGENCompugen$1.34-4.3%$1.49$1.13▼$2.66$119.58M2.58232,459 shs631,966 shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$36.19M0.8114,627 shs2,403 shsSKYESkye Bioscience$4.25-0.2%$3.72$1.14▼$6.22$131.71M2.34274,437 shs242,412 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+16.07%-5.47%+28.80%+880,999,900.00%CGENCompugen0.00%-6.29%-6.29%-18.79%-31.98%PYRGFPyroGenesis Canada0.00%+1.53%-25.22%-45.06%-67.86%SKYESkye Bioscience0.00%+6.25%+21.08%+99.06%-29.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6755.13% UpsideCGENCompugen 3.00Buy$4.00198.51% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ASKYESkye Bioscience 3.14Buy$15.50264.71% UpsideCurrent Analyst Ratings BreakdownLatest PYRGF, SKYE, CGEN, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/14/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$15.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$25.19M5.74N/AN/A$0.08 per share110.13CGENCompugen$27.86M4.29N/AN/A$0.62 per share2.16PYRGFPyroGenesis Canada$9.14M3.96N/AN/A($0.01) per share-19.30SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.70N/AN/AN/A-39.95%-11,357.84%-39.94%11/24/2025 (Estimated)CGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ASKYESkye Bioscience-$26.57M-$1.06N/AN/AN/AN/A-76.03%-69.20%N/ALatest PYRGF, SKYE, CGEN, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BHSTBioHarvest Sciences-$0.1075-$0.15-$0.0425-$0.24$8.53 million$8.52 million8/7/2025Q2 2025SKYESkye Bioscience-$0.34-$0.44-$0.10-$0.44N/AN/A8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.600.36CGENCompugenN/A4.744.74PYRGFPyroGenesis CanadaN/A0.600.50SKYESkye BioscienceN/A6.096.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACGENCompugen12.22%PYRGFPyroGenesis Canada0.03%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACGENCompugen9.50%PYRGFPyroGenesis Canada47.68%SKYESkye Bioscience3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.42 millionN/AN/ACGENCompugen7089.24 million80.76 millionOptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataSKYESkye Bioscience1130.99 million30.06 millionOptionablePYRGF, SKYE, CGEN, and BHST HeadlinesRecent News About These CompaniesSkye Bioscience (SKYE) Receives a Buy from Citizens JMPSeptember 12 at 10:26 AM | theglobeandmail.comCantor Fitzgerald Sticks to Its Buy Rating for Skye Bioscience (SKYE)September 12 at 10:26 AM | theglobeandmail.comSkye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comSkye Bioscience (SKYE) Gets a Buy from Craig-HallumSeptember 6, 2025 | theglobeandmail.comSkye Bioscience Advances Position In Competitive Obesity Market With Promising DataSeptember 5, 2025 | benzinga.comSkye Bioscience reports results from two preclinical DIO studies on nimacimabSeptember 4, 2025 | msn.comSkye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide ...September 4, 2025 | theglobeandmail.comSkye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO ModelSeptember 4, 2025 | globenewswire.comSkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ StudySeptember 3, 2025 | markets.businessinsider.comSkye Bioscience, Inc.: Skye Completes 26-week Treatment Phase in Phase 2a CBeyond StudySeptember 2, 2025 | finanznachrichten.deSkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ StudySeptember 2, 2025 | globenewswire.comSkye Bioscience to host KOL event on CBeyond Phase 2a clinical data readoutAugust 27, 2025 | msn.comSkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutAugust 27, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by AnalystsAugust 24, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 SharesAugust 23, 2025 | insidertrades.comSkye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025August 21, 2025 | quiverquant.comQSkye Bioscience to Participate in Upcoming Investment and Medical ConferencesAugust 21, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy RatingAugust 18, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform RecommendationAugust 16, 2025 | msn.comEvercore starts Skye Bioscience at Outperform on nimacimab potentialAugust 14, 2025 | msn.comSkye Bioscience initiated with an Outperform at Evercore ISIAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYRGF, SKYE, CGEN, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$8.81 +1.48 (+20.19%) As of 09/12/2025 03:58 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Compugen NASDAQ:CGEN$1.34 -0.06 (-4.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.39 +0.05 (+3.73%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.PyroGenesis Canada NASDAQ:PYRGF$0.19 +0.02 (+11.18%) As of 09/12/2025 03:06 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Skye Bioscience NASDAQ:SKYE$4.25 -0.01 (-0.23%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.26 +0.01 (+0.24%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
